LONDON, Sept. 17, 2002 (PRIMEZONE) -- Interview available now on www.cantos.com with Elliott D. Hillback Jr., Senior Vice-President Corporate Affairs.
Why Genzyme (Nasdaq:GENZ) has reduced earnings guidance for Renagel for the third time in 6 months; near term FDA actions on Fabrazyme and Aldurazyme and the 600 million dollar potential of Cerezyme for the treatment of type 1 Gauchers disease.
Interviews with AFFYMETRIX, SEPRACOR and VERTEX also available on Cantos today.
This interview is available in video, audio and transcript.
It's free to view. All you need to do is register at http://www.cantos.com
Cantos.com is an online financial website where top management of companies address the critical issues facing their businesses.
If you would like to contact us, please email enquiries@cantos.com.